These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26818116)

  • 1. Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
    Schroeder M; Viezens L; Wellbrock J; Fiedler W; Rüther W; Algenstaedt P; Hansen-Algenstaedt N; Schaefer C
    J Surg Oncol; 2016 Apr; 113(5):515-21. PubMed ID: 26818116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microcirculation of secondary bone tumors in vivo: the impact of minor surgery at a distal site.
    Schaefer C; Fuhrhop I; Schroeder M; Viezens L; Otten J; Fiedler W; Rüther W; Hansen-Algenstaedt N
    J Orthop Res; 2010 Nov; 28(11):1515-21. PubMed ID: 20872590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone.
    Schaefer C; Schroeder M; Fuhrhop I; Viezens L; Otten J; Fiedler W; Rüther W; Hansen-Algenstaedt N
    J Orthop Res; 2011 Aug; 29(8):1251-8. PubMed ID: 21381098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.
    Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Clohisy DR; Dudek AZ
    Eur J Cancer; 2008 Nov; 44(16):2506-17. PubMed ID: 18723339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
    Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
    Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of microvascular remodelling during tumor growth in bone.
    Fuhrhop I; Schroeder M; Rafnsdóttir SL; Viezens L; Rüther W; Hansen-Algenstaedt N; Schaefer C
    J Orthop Res; 2010 Jan; 28(1):27-31. PubMed ID: 19642113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
    Argyros O; Karampelas T; Varela A; Asvos X; Papakyriakou A; Agalou A; Beis D; Davos CH; Fokas D; Tamvakopoulos C
    Oncotarget; 2017 Jun; 8(23):37250-37262. PubMed ID: 28422745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
    Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
    Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
    Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
    BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
    Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
    Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
    Schem C; Bauerschlag D; Bender S; Lorenzen AC; Loermann D; Hamann S; Rösel F; Kalthoff H; Glüer CC; Jonat W; Tiwari S
    BMC Cancer; 2013 Jan; 13():32. PubMed ID: 23347638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
    El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
    Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
    Bäuerle T; Merz M; Komljenovic D; Zwick S; Semmler W
    Clin Cancer Res; 2010 Jun; 16(12):3215-25. PubMed ID: 20530698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
    Klenke FM; Gebhard MM; Ewerbeck V; Abdollahi A; Huber PE; Sckell A
    BMC Cancer; 2006 Jan; 6():9. PubMed ID: 16409625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
    Bauerschlag DO; Schem C; Tiwari S; Egberts JH; Weigel MT; Kalthoff H; Jonat W; Maass N; Meinhold-Heerlein I
    Anticancer Res; 2010 Sep; 30(9):3355-60. PubMed ID: 20944108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
    Matsumoto S; Saito K; Takakusagi Y; Matsuo M; Munasinghe JP; Morris HD; Lizak MJ; Merkle H; Yasukawa K; Devasahayam N; Suburamanian S; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2014 Sep; 21(8):1145-55. PubMed ID: 24597714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.